Caseware UK (AP4) 2023.0.135 2023.0.135 2024-12-312024-12-312024-01-01trueNo description of principal activity22truefalse 03934884 2024-01-01 2024-12-31 03934884 2023-01-01 2023-12-31 03934884 2024-12-31 03934884 2023-12-31 03934884 c:Director12 2024-01-01 2024-12-31 03934884 d:Non-currentFinancialInstruments 2024-12-31 03934884 d:Non-currentFinancialInstruments 2023-12-31 03934884 d:ShareCapital 2024-12-31 03934884 d:ShareCapital 2023-12-31 03934884 c:EntityNoLongerTradingButTradedInPast 2024-01-01 2024-12-31 03934884 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 03934884 c:AbridgedAccounts 2024-01-01 2024-12-31 03934884 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 03934884 c:Micro-entities 2024-01-01 2024-12-31 03934884 e:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Registered number: 03934884










DEXAPHARM LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2024

 
DEXAPHARM LIMITED
REGISTERED NUMBER: 03934884

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

  

Current assets
  

Debtors: amounts falling due after more than one year
 2 
9,009
9,009

  
9,009
9,009

Total assets less current liabilities
  
 
 
9,009
 
 
9,009

  

Net assets
  
9,009
9,009


Capital and reserves
  

Called up share capital 
  
9,009
9,009

  
9,009
9,009


Notes


Average number of employees

The average monthly number of employees, including directors, during the year was 2 (2023 - 2).

The Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

The members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities' regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 30 April 2025.




Mrs P V Mistry
Director

Page 1

 
DEXAPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.Accounting policies

 
1.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 105 the UK and the Republic of Ireland and the Companies Act 2006.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A) of the Companies Act 2006.


2.


Debtors

2024
2023
£
£

Due after more than one year

Amounts owed by group undertakings
9,009
9,009

9,009
9,009



3.


Controlling party

At the balance sheet date, the company is wholly-owned subsidiary of Esom's Ltd, a company incorporated in England and Wales and trading in United Kingdom. 

Page 2